Tuesday 27 April 2004
Definition: In 1956, Castleman et al. described an entity involving localized mediastinal lymph node hyperplasia that resembled thymoma. Castleman disease is a distinct form of lymph node hyperplasia occurring in two morphologic patterns; hyaline vascular and plasma cell type.
The former usually presents as a single large mass (unicentric Castleman’ s disease) and the later has plasma cell infiltrates and is multicentric. Multicentric form is associated with immune deficiency states, HIV, HHV8 infection, POEMS syndrome and also secondary to increase of cytokine activity (IL-6).
Castleman disease (CD) has been extended to include two entities: the classical hyaline-vascular (HV) type and the rare plasma cell variant.
The disease appears to be polyclonal in origin in the majority of cases, however evidence for clonal expansion was documented in some cases, possibly representing transformation into non Hodgkin’s lymphoma.
In approximately 1/3 of the cases studied a monoclonal IgH rearrangement was documented. A minor T-cell clone, mostly in a polyclonal background, was also documented in some cases.
The disease is very rare.
The disease may present as a solitary mass frequently occurring in the mediastinum or as a systemic disorder (multicentric Castleman disease) with diffuse adenopathies, systemic symptoms and recurrent infections.
Splenomegaly, hepatomegaly and neurologic symptoms may occur frequently as is the case with autoimmune manifestations.
There are two variants: the hyaline-vascular type and the plasma cell type.
In the hyaline-vascular type, there are shrunken germinal centres with concentric expansion of the mantle zones with eosinophils and hyalinization around the vessels.
In the plasma cell type, an extensive infiltrate by plasma cells is seen in the interfollicular areas. Some patients may be infected by human herpervirus-8 (HHV-8) which may induce interleuchin-6 (IL-6 or IL6) overproduction. IL-6 is believed to play an essential role in the pathogenesis of the disease.
The hyaline-vascular type is usually diagnosed in asymptomatic patients whereas systemic symptoms are present in the majority of patients with the plasma cell subtype. Patients with multicentric Castleman disease show histologic features consistent with the plasma cell subtype.
HHV8-associated plasmacytic Castleman disease (plasma cell type Castleman disease)
hyaline–vascular type Castleman disease (or angiofollicular Castleman disease)
- In the hyaline-vascular type, numerous lymphoid follicles contain small germinal centers, some of which are depleted lymphocytes and composed of concentrically arranged eosinophilic cells penetrated by small capillaries, so-called hyaline-vascular lesions. Vascular proliferation in the interfollicular area is also present.
- However, the hyaline-vascular type of germinal center is not specific for Castleman disease.
solitary form of Castleman disease (localized Castleman disease)
multicentric form of Castleman disease
lymph nodes (nodal Castleman disease)
extranodal Castleman disease
- subcutis of the extremities and trunk (#15105643#)
- skeletal muscles of the extremities and trunk (#15105643#)
- mediastinal Castleman disease
- retroperitoneal Castleman disease
- pulmonary Castleman disease
hyaline vascular type-Castleman disease (HVCD)
plasmacytic type-Castleman disease (PCD)
mixed pattern type-Castleman disease
follicular dendritic cell dysplasia
follicular dendritic cell sarcoma
Castleman disease is a morphologically distinct form of lymph node hyperplasia rather than neoplasm or hamartoma.
The dendritic follicular cells are thought by some authors to be at core of pathogenesis of hyaline vascular type Castleman disease.
Neoplastic potential: appears to manifest mainly through development of:
- lymphoid tumors in plasma cell type
- dendritic cell tumors/stromal tumors in vascular hyaline type
- exceptions are isolated cases of dendritic/stromal tumors in vascular hyaline type accompanied or preceded by plasmacytoma, follicular lymphoma, Hodgkin lymphoma
High-grade spindle cell sarcomas may develop:
- originally interpreted as probable vascular nature because myoid tumor cells closely apposed to vascular structures
- not clear whether myoid cells are truly vessel-related or originate from another member of the reticulum/dendritic cell family (so-called fibroblastic reticulum cells, myoid reticulum cells, or dychthyocytes)
Many of the cases so far studied showed a normal karyotyope.
Occasional abnormalities were found in a few patients:
- One case with the hyaline vascular type showed a t(1;6)(p11;p11), a del(7)(q21q22) and a del(8)(q12q22). In this patient no clonal expansion of lymphoid cells was present, suggesting that the clonal proliferation involved dysplastic stromal cells.
- Another patient was shown to carry a clonal abnormality in CD21-positive follicular dendritic cells.
- Abnormal chromosomes in this patient were add(1)(q21), der(6)t(6;12)(q23;q15), add(7)(p22), -9, inv(9)p11q13), del(12)(q15).
- One patient carried a t(7;14)(p22;q22).
The patients can be treated by surgical excision if the mass is localized. Steroid treatment is recommended in cases with disseminated disease and combination chemotherapy utilized for lymphoma must be reserved to unresponsive patients. Some patients with HIV associated Castleman’s disease were successfully treated with the anti CD20 monoclonal antibody or with the antiviral agent ganciclovir targeting the HHV-8.
The prognosis varies greatly depending on the histologic type and disease presentation. If the disease is localized, surgery with or without radiotherapy may be curative. Those patients with multicentric disease who fail to respond to steroid treatment have a serious disease.
Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman’s disease. Association with Epstein-Barr virus.
Hanson CA, Frizzera G, Patton DF, Peterson BA, McClain KL, Gajl-Peczalska KJ, Kersey JH . The American journal of pathology. 1988 ; 131 (1) : 84-91.
Atypical Lymphoproliferative Diseases. Greiner T, Armitage JO, Gross TG
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2000 : 133-146. PMID #11701539#
[Chromosomal abnormalities in Castleman’s disease with high levels of serum interleukin-6] Nakamura H, Nakaseko C, Ishii A, Kogure K, Kawano E, Hashimoto S, Nishimura M, Matsuura Y, Oh H, Yoshida S
[Rinsho ketsueki] The Japanese journal of clinical hematology. 1993 ; 34 (2) : 212-217. PMID #8492420#
Molecular analysis of clonality in Castleman’s disease. Soulier J, Grollet L, Oksenhendler E, Micla JM, Cacoub P, Baruchel A, Brice P, Clauvel JP, d’Agay MF, Raphael M. Blood. 1995 ; 86 (3) : 1131-1138. PMID #7620166#
A chromosomal abnormality in hyaline vascular Castleman’s disease: evidence for clonal proliferation of dysplastic stromal cells. Pauwels P, Dal Cin P, Vlasveld LT, Aleva RM, van Erp WF, Jones D. The American journal of surgical pathology. 2000 ; 24 (6) : 882-888. PMID #10843293#
Atypical lymphoproliferative disorders. Frizzera G In Knowles DM (Ed) Neoplastic hemopathology IInd edition..
Lack of cytogenetic abnormalities in Castleman’s disease. Menke DM, DeWald GW Southern medical journal. 2001 ; 94 (5) : 472-474. PMID #11372793#
Hyaline vascular Castleman’s disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. Cokelaere K, Debiec-Rychter M, De Wolf-Peeters C, Hagemeijer A, Sciot R; The American journal of surgical pathology. 2002 ; 26 (5) : 662-669. PMID #11979097#
Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Casper C, Nichols WG, Huang ML, Corey L, Wald A. Blood. 2004 ; 103 (5) : 1632-1634. PMID #14615380#
A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. Annals of hematology. 2003 ; 82 (12) : 766-768. PMID #12898190#
Rituximab therapy for HIV-associated Castleman disease. Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, Calvez V, Dupin N. Blood. 2003 ; 102 (8) : 2786-2788. PMID #12842986#
Smir BN, Greiner TC, Weisenburger DD. Multicentric angiofollicular lymph node hyperplasia in children: a clinicopathologic study of eight patients. Mod Pathol. 1997;9:1135–1142.
Gulati P, Sun NC, Herman BK, Said JW, Cornford ME. Isolated leptomeningeal Castleman’s disease with viral particles in the follicular dendritic cells. Arch Pathol Lab Med. 1998;122:1026–1029.
Menke DM, Camoriano JK, Banks PM. Angiofollicular lymph node hyperplasia. A comparison of unicentric, multicentric, hyaline vascular, and plasma cell types of disease by morphometric and clinical analysis. Mod Pathol. 1992;5:525–530.
Skelton HG, Smith KJ. Extranodal multicentric Castleman’s disease with cutaneous involvement. Mod Pathol. 1998;11:93–98.
Frizzera G, Banks PM, Massarelli G, Rosai J. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Pathological findings in 15 patients. Am J Surg Pathol. 1983;7:211–231.
Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Clinical findings and clinicopathologic correlations in 15 patients. J. Clin Oncol. 1985;3:1202–1216.
Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia. A clinicopathologic study of 16 cases. Hum Pathol. 1985;16:162–172.
Mandler RN, Kerrigan DP, Smart J, Kuis W, Villiger P, Lotz M. Castleman’s disease in POEMS syndrome with elevated interleukin-6. Cancer. 1992;69:2697–2703.
Munoz G, Geijo P, Moldenhauer F, Perez-Moro E, Razquin J, Piris MA. Plasmacellular Castleman’s disease and POEMS syndrome. Histopathology. 1990;17:172–174.
Chan JK, Fletcher CD, Hicklin GA, Rosai J. Glomeruloid hemangioma. A distinctive cutaneous lesion of multicentric Castleman’s disease associated with POEMS syndrome. Am J Surg Pathol. 1990;14:1036–1046.
Altiparmak MR, Pamuk GE, Pamuk ON, Dogusoy G. Secondary amyloidosis in Castleman’s disease: review of the literature and report of a case. Ann Hematol. 2002;81:336–339.
Ordi J, Grau JM, Junque A, Nomdedeu B, Palacin A, Cardesa A. Secondary (AA) amyloidosis associated with Castleman’s disease. Report of two cases and review of the literature. Am J Clin Pathol. 1993;100:394–397.
Peterson BA, Frizzera G. Multicentric Castleman’s disease. Semin Oncol. 1993;20:636–647.
Nguyen DT, Diamond LW, Hansmann ML, Alavaikko MJ, Schroder H, Fellbaum C, et al. Castleman’s disease. Differences in follicular dendritic network in the hyaline vascular and plasma cell variants. Histopathology. 1994;24:437–443.
Ruco LP, Gearing AJ, Pigott R, Pomponi D, Burgio VL, Cafolla A, et al. Expression of ICAM-1, VCAM-1 and ELAM-1 in angiofollicular lymph node hyperplasia (Castleman’s disease). Evidence for dysplasia of follicular dendritic reticulum cells. Histopathology. 1991;19:523–528.
Isaacson PG. Commentary: Castleman’s disease. Histopathology. 1989;14:429–432.
Amin HM, Medeiros LJ, Manning JT, Jones D. Dissolution of the lymphoid follicle is a feature of the HHV8+ variant of plasma cell Castleman’s disease. Am J Surg Pathol. 2002;27:91–100.
Ascoli V, Sirianni MC, Mezzaroma I, Mastroianni CM, Vullo V, Andreoni M, et al. Human herpesvirus-8 in lymphomatous and nonlymphomatous body cavity effusions developing in Kaposi’s sarcoma and multicentric Castleman’s disease. Ann Diagn Pathol. 2000;3:357–363.
Parravicini C, Chandran B, Corbellino M, Berti E, Pauli M, Moore PS, et al. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases. Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol. 2000;156:743–749.
Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Rogendorf M, Schwartz RA, et al. Update on Kaposi’s sarcoma and other HHV-8 associated disease. Part 2: Pathogenesis, Castleman’s disease, and pleural effusion lymphoma. Lancet Infect Dis. 2002;2:344–352.
Menke DM, Chadbum A, Cesarman E, Green E, Berenson J, Said J, et al. Analysis of the human herpesvirus 8(HHV-8) genome and HHV-8 vIL-6 expression in archival cases of Castleman disease at low risk for HIV infection. Am J Clin Pathol. 2002;117:268–275.
Gould SJ, Diss T, Isaacson PG. Multicentric Castleman’s disease in association with a solitary plasmacytoma. A case report. Histopathology. 1990;17:135–140.
Rolon PG, Audouin J, Diebold J, Rolon PA, Gonzalez A. Multicentric angiofollicular lymph node hyperplasia associated with a solitary osteolytic costal IgG lambda myeloma. POEMS syndrome in a South American (Paraguayan) patient. Pathol Res Pract. 1989;185:468–469.
Larroche C, Cacoub P, Soulier J, Oksenhendler E, Chauvel JP, Piette JC, et al. Castleman’s disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol. 2002;69:119–126.
Vasef M, Katzin WE, Mendelsohn G, Reydman M. Report of a case of localized Castleman’s disease with progression to malignant lymphoma. Am J Clin Pathol. 1992;98:633–636.
Abdel-Reheim FA, Koss W, Rappaport ES, Arber DA. Coexistence of Hodgkin’s disease and giant lymph node hyperplasia of the plasma-cell type (Castleman’s disease). Arch Pathol Lab Med 196, 120: 91-96.
Maheswaran PR, Ramsay AD, Norton AJ, Roche WR. Hodgkin’s disease presenting with the histological features of Castleman’s disease. Histopathology. 1991;18:249–253.
Zarate-Osorno A, Medeiros LJ, Danon AD, Neiman RS. Hodgkin’s disease with coexistent Castleman-like histologic features. A report of three cases. Arch Pathol Lab Med. 1994;118:270–274.
Gerald W, Kostianovsky M, Rosai J. Development of vascular neoplasia in Castleman’s disease. Report of seven cases. Am J Surg Pathol. 1990;14:603–614.
Frizzera G. Castleman’s disease and related disorders. Semin Diagn Pathol. 1988;5:346–364.
Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of mediastinum and other locations. Cancer. 1972;29:670–683.
Cokelaere K, Debiec-Rychter M, De Wolf-Peeters C, Hagemeijer A, Sciot R. Hyaline vascular Castleman’s disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. Am J Surg Pathol. 2002;26:662–669.
Pauwels P, Dal Cin P, Vlasved LT, Aleva RM, van Erp WF, Jones D. A chromosomal abnormality in hyaline vascular Castleman’s disease: evidence for clonal proliferation of dysplastic stromal cells. Am J Surg Pathol. 2000;24:882–888.
Chan JK, Tsang WY, Ng CS. Follicular dendritic cell tumor and vascular neoplasm complicating hyaline-vascular Castleman’s disease. Am J Surg Pathol. 1994;18:517–525.
Lin O, Frizzera G. Angiomyoid and follicular dendritic cell proliferative lesions in Castleman’s disease of hyaline-vascular type: a study of 10 cases. Am J Surg Pathol. 1997;21:1295–1306.
Danon AD, Krishnan J, Frizzera G. Morpho-immunophenotypic diversity of Castleman’s disease, hyaline-vascular type. With emphasis on a stroma-rich variant and a new pathogenetic hypothesis. Virchows Arch [A]. 1993;423:369–382.
Nagai K, Sato I, Shimoyama N. Pathohistological and immunohistochemical studies on Castleman’s disease of the lymph node. Virchows Arch [A]. 1986;409:287–297.
Madero S, Oñate JM, Garzón A. Giant lymph node hyperplasia in an angiolipomatous mediastinal mass. Arch Pathol Lab Med. 1986;110:853–855.
Menke DM, Tiemann M, Camoriano JK, Chang SF, Madan A, Chow M, et al. Diagnosis of Castleman’s disease by identification of an immuno-phenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol. 1996;105:268–276.
Jones EL, Crocker J, Gregory J, Guibarra M, Curran RC. Angiofollicular lymph node hyperplasia (Castleman’s disease). An immunohistochemical and enzyme-histochemical study of the hyaline-vascular form of lesion. J Pathol. 1984;144:131–147.
Hsu SM, Waldron JA, Xie SS, Barlogie B. Expression of interleukin6 in Castleman’s disease. Hum Pathol. 1993;24:833–839.
Kojima M, Nakamura S, Shimizu K, Itoh H, Yamane Y, Murayama K, Tanaka H, Sugihara S, Shimano S, Sakata N, Masawa N. Clinical implication of idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinemia. A report of 16 cases. Int J Surg Pathol(in press).
Hall PA, Donaghy M, Cotter FE, Stansfeld AG, Levison DA. An immunohistological and genotypic study of the plasma cell form of Castleman’s disease. Histopathology. 1989;14:333–346.
Hanson CA, Frizzera G, Patton DF, Peterson BA, McClain KL, Gajl-Peczalska KJ, et al. Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman’s disease. Association with Epstein–Barr virus. Am J Pathol. 1988;131:84–91.
Ohyashiki JH, Ohyashiki K, Kawakubo K, Serizawa H, Abe K, Mikata A, et al. Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman’s disease of the plasma cell type. Am J Clin Pathol. 1994;101:290–295.
Radaszkiewicz T, Hansmann ML, Lennert K. Monoclonality and polyclonality of plasma cells in Castleman’s disease of the plasma cell variant. Histopathology. 1989;14:11–24.
Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, et al. The management of unicentric and multicentric Castleman’s disease. A report of 16 cases and a review of the literature. Cancer. 1999;85:706–717.